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ELUCIDATION OF A 
TRIPARTITE MECHANISM 
UNDERLYING THE 
IMPROVEMENT IN 
CARDIAC TOLERANCE TO 
ISCHEMIA BY COENZYME 
Qlo PRETREATMENT 
Coenzyme Qlo, which is involved in mitochondrial adenosine triphosphate 
production, is also a powerful antioxidant. We hypothesize that coenzyme Qlo 
pretreatment protects myocardium from ischemia reperfusion injury both by 
its ability to increase aerobic energy production and by protecting creatine 
kinase from oxidative inactivation during reperfusion. Isolated hearts (six per 
group) from rats pretreated with either coenzyme Qlo, 20 mg/kg intramuscu- 
larly and 10 mg/kg intraperitoneally (treatment) or vehicle only (control) 24 
and 2 hours before the experiment were subjected to 15 minutes of equilibra- 
tion, 25 minutes of ischemia, and 40 minutes of reperfusion. Developed 
pressure, contractility, compliance, myocardial oxygen consumption, and 
myocardial aerobic efficiency were measured. Phosphorus 31 nuclear magnetic 
resonance (31P-NMR) spectroscopy was used to determine adenosine triphos- 
phate and phosphocreatine concentrations as a percentage of a methylene 
diphosphonic acid standard. Hearts were assayed for myocardial coenzyme 
Qlo and myocardial creatine kinase activity at end equilibration and at 
reperfusion. Treated hearts showed higher myocardial coenzyme Qlo levels 
(133 +- 5/.tg/gm ventricle versus 117 -+ 4/~g/gm ventricle, p < 0.05). Developed 
pressure at end reperfusion was 62% + 2% of equilibration in treatment group 
versus 37% -+ 2% in control group, p < 0.005. Preischemic myocardial aerobic 
efficiency was preserved uring reperfusion in treatment group (0.84 - 0.08 
mm Hg/(/xl O2/min/gm ventricle) vs 1.00 +- 0.08 mm Hg/(/xl O2/min/gm 
ventricle) at equilibration, p = not significant), whereas in the control group it 
fell to 0.62 - 0.07 mm Hg/(/xl O2/min/gm ventricle, p < 0.05 vs equilibration 
and vs the treatment group at reperfusion. Treated hearts showed higher 
adenosine triphosphate and phosphocreatine levels during both equilibration 
(adenosine triphosphate 49% _+ 2% for the treatment group vs 33% _+ 3% in 
the control group, p < 0.005; phosphocreatine 49% --. 3% in the treatment 
group vs 35% -+ 3% in the control group, p < 0.005) and reperfusion 
(adenosine triphosphate 18% _+ 3% in the treatment group vs 11% - 2% in the 
control group, CTRL p < 0.05; phosphocreatine 45% - 2% in the treatment 
group vs 23% - 3% in the control group, p < 0.005). Creatine kinase activity 
in treated hearts at end reperfusion was 74% - 3% of equilibration activity vs 
65% -+ 2% in the control group, p < 0.05). Coenzyme Qlo pretreatment im- 
proves myocardial function after ischemia nd reperfusion. This results from 
a tripartite effect: (1) higher concentration of adenosine triphosphate and 
phosphocreatine, initially and during reperfusion, (2) improved myocardial 
aerobic efficiency during reperfusion, and (3) protection of creatine kinase 
from oxidative inactivation during reperfusion. (J THORAC CARDIOVASC SURG 
1996;111:443-50) 
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M Yocardial ischemia-reperfusion injury is associ- ated with toxic oxygen metabolite production 
that causes lipid and protein peroxidation and ener- 
getic derangements as a result of alterations in 
energy synthesis, transfer, or useJ  -5 Oxygen radical 
scavengers and agents that modulate nergy use and 
production have been used to prevent or attenuate 
this injury. 6-10 Coenzyme Qlo (CoQ~o) has both of 
these properties. 11 
CoQio is a lipid-soluble benzoquinone that has 
properties potentially useful in preventing or atten- 
uating the damage associated with ischemia and 
reperfusionJl, 12 CoQ1 ° is directly involved in en- 
ergy transduction and aerobic adenosine triphos- 
phate (ATP) production; it transports electrons in 
the respiratory chain and Couples th e respiratory 
chain to oxidative phosphorylationJ 346 CoQm is a 
regenerable and powerful anti0xidant, capable of 
protecting cell structures from oxidative damage 
during reperfusion. 17-19 It also regenerates vitamin 
E from the tocopheroxyl radical produced by free 
oxygen radicals. 17 The antioxidant actions of CoQ~o 
are not limited to the mitochondria but are applica- 
ble to any other cell membrane containing CoQ10 .17 
These properties make CoQ10 an ideal therapeutic 
agent to reduce myocardial ischemia-reperfusion 
injury. 20-22 
Creatine kinase (CK) is a crucial enzyme involved 
in the metabolism of high-energy phosphates. CK 
is exquisitely sensitive to oxidation and has 
been shown to be  susceptible to inactivation by 
toxic oxygen metabolites during reperfusion, im- 
pairing the transfer of high-energy phosphates 
between phosphocreatine and adenosine diphos- 
phate.4, 5, 23, 24 We hypothesized that COQlo pre- 
treatment protects myocardium from ischemia 
reperfusion injury by increasing aerobic energy pro- 
duction and by protecting CK from oxidative inac- 
tivation during reperfusion. 
Method 
Pretreatment with CoQ1 o. Male Sprague-Dawley rats 
weighing 200 to 250 gm (six per group) were divided into 
two groups. The CoQm group was pretreated with CoQlo 
(20 mg/kg intramuscularly and 10 mg/kg intraperitoneally; 
Pharma Nord, Vojens, Denmark), control group was 
pretreated with vehicle only (dimethyl sulfoxide, Sigma 
Chemical Co., St. Louis, Mo.); both groups underwent 
pretreatment 24hours and 2 hours before the experiment. 
Isolated heart preparation. Rats were anesthetized 
with sodium pentobarbital (60 mg/kg intraperitoneally) 
and heparin sodium (500 IU intraperitoneally) in accor- 
dance with the "Principles of Laboratory Animal Care" 
formulated by the National Society for Medical Research 
and the "Guide for the Care and Use of Laboratory 
Animals" prepared by the Institute of Laboratory Animal 
Resources and published by the National institutes of 
Health (NIH Publication No. 86-23, revised 1985). Hearts 
were excised quickly and arrested in a 4 ° C Krebs-Hense- 
leit solution of the following composition: sodium chlo- 
ride, 118 retool/L; potassium chloride, 4.6 mmol/L; potas- 
sium phosphate, 1.17 mmol/L; magnesium sulfate, 1.17 
mmol/L; calcium chloride, 1.16 mmolYL; sodium bicarbon- 
ate, 23 mmol/L; and glucose, 5.3 mmol/L. The hearts were 
then transferred to a nonrecirculating Langendorff appa- 
ratus and perfused at a constant aortic pressure of 76 mm 
Hg at 37 ° C with Krebs-Henseleit solution (pH 7.4, oxygen 
tension > 500 mm Hg), previously equilibrated with a 
gas mixture of 92.5% oxygen and 7.5% carbon dioxide. 
Hearts were paced at 360 beats/min at two times 
threshold (Grass Instrument Co., Quincy, Mass. ). An 
intraventricular latex balloon was inserted in the left 
ventricle through the mitral valve and attached to a 
pressure transducer (COBE Laboratories, Inc., Lake- 
wood, Colo.). Left ventricular end-diastolic pressure was 
set at 6 mm Hg. Developed pressure (DP; peak systolic 
pressure minus end-diastolic pressure), contractility 
(+dP/dt), and compliance (-dP/dt) were recorded 
throughout the experiment. Coronary flow was measured 
by a digital flow meter (Humonics, Rancho Cordova, 
Calif.) by measuring pulmonary artery effluent. Data were 
amplified, acquired, and recorded on a Macintosh IIci 
computer (Apple Computer, Inc., Cupertino, Calif.) with 
LabView software (National Instruments, Austin, Texas). 
Experimental protocol. Hearts were subjected to 15 
minutes of equilibration, 25 minutes of global normother- 
mic ischemia, and 40 minutes of reperfusion. Ischemia 
was achieved by means of a stopcock at the level of the 
aortic root. Pacing was halted during ischemia, and heart 
temperature was maintained at 37 ° C by immersion in a 
water-jacketed, nongassed Perfusate bath. 
Determination of myocardial oxygen consumption 
(MVoz) and myocardial aerobic efficiency (DP/MVo2). At 
end-equilibration a d at end-reperfusion, oxygen tension 
was determined with a blood gas analyzer (Corning-170 
pH/Blood Gas Analyzer; Coming Inc., Medfield, Mass,) 
from perfusate samples drawn from the aortic cannula 
and from the coronary sinus. MVo~ (/xl o2/min/gm ventri- 
cle, wet weight) was determined from the following for- 
mula: 
MVo2 = (Solubility of oxygen at 37 ° C) × (pao: - PcsO2) 
× CF/Wet weight of ventricle. 
where pao 2 represents oxygen tension determined from 
perfusate drawn from the aortic cannula, pcsOz represents 
oxygen tension in perfusate drawn from the coronary 
sinus, and CF represents coronary flow. DP/MV02 was 
defined as the ratio between DP (in millimeters of mer- 
cury) and MVo 2. 
Determination of CK activity in heart tissue. Control 
and CoQlo hearts (six per group) were perfused for 15 
minutes to determine baseline (preischemic) CK activity. 
After ischemia t the end of the 40 minutes of reperfu- 
sion, left and right ventricles were freeze clamped in liquid 
nitrogen and stored at -70 ° C. Tissue samples were 
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Fig. 1. Recovery of mechanical function during reperfusion expressed as a percentage ofend-equilibration 
left ventricular DP. Asterisk indicates p < 0.005 versus control. Note improvement afforded by CoQlo 
pretreatment. 
weighed, placed in 10 volumes/weight of cold isolation 
buffer (5 mmol/L potassium phosphate, 0.3 mol/L sucrose, 
5 mmol/L morpholino propanesulfonic acid and 0.2 
mmol/L ethylenediamintetraacetic acid, pH 7.4), and ho- 
mogenized at 4°C during 20 seconds with a Tekmar 
Tissumizer (Tekmar Co., Cincinnati, Ohio). Homoge- 
nates were centrifuged at 0°C for 10 minutes at 2000g. 
The supernatant was diluted to less than 1000 IU/L before 
assay of CK activity. The assay was performed with Sigma 
diagnostic kit no. 47-UV (Sigm a Chemical Co.) on a 
Beckman DU 640 spectrophotometer (Beckman Instru- 
ments, Inc., Fullerton, Calif.) in quartz cuvettes main- 
tained at 30 ° C. Values were expressed as international 
units per gram of ventricle. 
Determination of preischemie CoQ1 o concentrations in 
heart tissue. Control and CoQm hearts (six per group) 
were perfused for 15 minutes. Hearts were freeze clamped 
in liquid nitrogen and stored at -70 ° C. CoQlo levels were 
determined according to the procedure described by 
Edlund. 25 Briefly, tissue samples were homogenized partly 
enzymatically (with collagenase in ultrabath) and partly 
mechanically. After extraction with 1-propanol and the 
addition of an internal standard (coenzyme Qll), the 
residue was subjected to high-performance liquid chroma- 
tography with electrochemical detection, yielding the total 
tissue content of both COQlo and coenzyme Qg' Levels are 
expressed as micrograms per gram of dry ventricle. 
Evaluation of high-energy phosphate metabolites. Par- 
allel groups of hearts (six per group) were perfused 
according to the previously described protocol within a 
11.5 Tesla Bruker AM 500 spectrometer (Bruker Medical 
Instruments, Inc., Billerica, Mass.) and phosphorus 31 
nuclear magnetic resonance (31p-NMR) spectra were 
acquired. A capillary tube with a standard concentration 
of methylene diphosphonic acid (MDP) was placed next 
to the heart inside the NMR tube to act as an absolute 
standard. 31p-NMR spectra were obtained every 10 min- 
utes with 416 45-degree angle pulses with an interpulse 
delay of 1 second. A line broadening of 15 Hz was used. 
Inorganic phosphate, phosphocreatine, ATP, and MDP 
areas were determined by triangulation. To correct for 
partial saturation, fully relaxed 31p-NMR spectra were 
obtained at a relaxation delay of 15 seconds, and correc- 
tion factors for inorganic phosphate, ATP, phosphocre- 
atine, and MDP were determined. Only the/3-ATP peak 
was used for ATP determination because the c~ and 3' 
peaks contain other phosphorylated nucle0tide bases. 
Values of inorganic phosphate, ATP, and phosphocre- 
atine are expressed as a percentage of the MDP standard 
as well as in terms of the percentage of their respective 
preischemic levels. Intracellular pH (pHi) was determined 
only during ischemia from the chemical shift of inorganic 
phosphate relative to phosphocreatine by applying the 
following equation: pH i = 6.77 - log[(2.52/[d - 3.22]) - 
1],26. 27 where d is the chemical shift in parts per million. 
During equilibration and reperfusion the presence of two 
overlapping inorganic phosphate peaks (intracellular and 
buffer) made it impossible to determine the inorganic 
phosphate concentration and pHi. 
Statistical analysis. Data are expressed as mean +_ 
standard error of the mean. Paired and nonpaired t tests 
were used for statistical significance. Significance was 
assumed for p < 0.05. 
Results 
Mechanical function. Hearts perfused for 80 
minutes of equilibration preserved 94% _+ 2% of 
their equilibration DP, justifying the stability of our 
model. Control and CoQ10 hearts had the same DP 
at end-equilibration (109 _+ 6 vs 107 + 5 mmHg, p = 
not significant [NS]). At end-reperfusion, CoQ10 
hearts recovered 62% + 2% of their preischemic 
DP whereas control hearts recovered only 37% +_ 
2% (p < 0.005 vs control, Fig. 1.) Both +dP/dt  and 
-dP /d t  behaved in a similar fashion. At end-reper- 
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Fig. 3. Myocardial CK activity at end-equilibration a d at end-reperfusion. Hearts pretreated with COOlo 
maintained greater CK activity than did control hearts. Asterisk indicates p < 0.05 versus control at 
reperfusion. V,,Ventricle. 
fusion, CoQ10 hearts had lower end-diastolic pres- 
sures than did control (40.8 + 2 vs 56 + 4 mm Hg, 
p < 0.005). The onset of contracture during isch- 
emia (7.7 _+ 0.4 vs 8.6 + 0.4 minutes, p = NS) and 
its degree at end-ischemia (44.1 _+ 2 vs 45 + 1 mm 
Hg, p = NS) were the same in both groups. 
DP/MVo 2. During equilibration, control and 
CoQ10 hearts had the same DP/MVo 2 (1.09 __ 0.08 
mm Hg/[/xl o2/min/gm ventricle) vs 1.00 + 0.08 mm 
Hg/(/xl o2/min/gm ventricle). At end reperfusion, 
however, CoQ10 hearts preserved their preischemic 
DP/MVo 2 (0.84 _+ 0.08 mm Hg/(/xl ojmin/gm ven- 
tricle), p = NS vs CoQ10 at equilibration). Control 
DP/MVo> however, fell to 0.62 _+ 0.07 mm Hg/(/M 
o2/min/gm ventricle), p < 0.05 vs control at equili- 
bration and vs CoQ10 at reperfusion (Fig. 2). 
CK activity. Preischemic CK activity was unaf- 
fected by CoQ10 pretreatment (590 + 29 1U/gm 
ventricle vs 590 _+ 26 IU/gm ventricle in control, p = 
NS). In control hearts, CK activity after 40 minutes 
of reperfusion fell to 390 _+ 10 IU/gm ventricle. 
CoQ10 hearts, however, lost less CK activity after 
reperfusion (435 + 17 IU/gm ventricle, p < 0.05 vs 
control during reperfusion; (Fig. 3). 
Preischemic myocardial CoQ1 o levels. Baseline 
myocardial CoQlo levels in CoQ10 hearts averaged 
133 _+ 5/xg/gm dry ventricle. They averaged 117 _+ 4 
/xg/gm dry ventricle in control hearts (p < 0.05). 
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3]P-NMR. At end-equilibration, hearts pre- 
treated with CoQlo showed higher phosphocreatine 
levels than did control (49% _+ 3% vs 35% _+ 3% 
MDP, p < 0.005) as well as higher ATP levels 
(49% _+ 2% vs 33% + 3% MDP, p < 0.005). These 
higher levels are maintained throughout reperfu- 
sion; by end-reperfusion, phosphocreatine levels in 
COQlo hearts were 45% _+ 2% versus 23% + 3% 
MDP in control hearts (p < 0.005), and ATP levels 
were 18% + 3% versus 11% + 2% MDP in control 
hearts (p < 0.05; Fig. 4 and 5). At end-ischemia, 
CoQs0 and control hearts howed similar ATP levels 
(10.5% +-- 3% vs 6.8% +_ 2.4% MDP, p = NS) and 
similar pH i (6.24 _+ 0.15 vs 6.27 _+ 0.15, p = NS). 
Phosphocreatine and ATP levels during reperfusion 
can be also expressed as a percentage of equilibra- 
tion levels (phosphocreatine 92% +- 7% in CoQ10 vs 
66% _+ 8% in control, p < 0.05; ATP 39% +_ 7% in 
CoQm vs 32% _+ 5% in control, p = NS). 
Discuss ion  
This experiment shows that CoQ10 pretreatment 
improves myocardial tolerance to ischemia reperfu- 
sion injury. Not only does CoQ10 improve the recov- 
ery of DP, it also improves diastolic function during 
reperfusion, as seen by a lower -dP/dt  and a lower 
end-diastolic pressure. 
Exogenously administered CoQ10 has been shown 
to nonspecifically incorporate into cell and mito- 
chondrial membranes. 28' 29 We have shown an incre- 
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ment in myocardial COQlo levels in rats pretreated 
with CoQao compared with control rats. Although 
COQlo synthesis decreases during ischemia, 3° hu- 
man and animal studies have shown that CoQlo 
pretreatment sufficient to increase preischemic 
CoQlo levels, as in our experimental model, pre- 
vents the myocardial COQlo depletion that normally 
occurs during ischemia nd reperfusion. 3°-33 
As a member of the respiratory chain, CoQlo is 
involved in the flux of electrons as well as in the 
coupling of the respiratory chain to oxidative phos- 
phorylation. 1316 CoQlo controls the efficiency of 
oxidative phosphorylation. 14 Exogenously adminis- 
tered COQlo appears to be able to increase the 
concentrations of high-energy phosphates, as shown 
by ATP and phosphocreatine levels during equili- 
bration. Although this increment in high-energy 
phosphate levels was not translated into better 
mechanical function before ischemia, during reper- 
fusion CoQlo hearts showed not only higher phos- 
phocreatine and ATP levels but also improved re- 
covery of mechanical function. Although this 
increment in aerobic energy production compared 
with control hearts could be sufficient o explain the 
improvement in mechanical function during reper- 
fusion, it is interesting that before ischemia the 
elevation in high-energy phosphate levels did not 
improve mechanical function. This apparent para- 
dox is obviously not addressed by evaluation of 
high-energy phosphate levels alone. The increment 
in ATP and phosphocreatine l vels seen during 
equilibration in CoQao hearts may limit myocardial 
damage during ischemia by better preserving cell 
structure and function, although our experiments 
were not designed to test this supposition. The 
observation that end-ischemic ATP levels and onset 
of contracture were similar in both groups is puz- 
zling and obviously requires further investigation. 
Myocardial CK, is inactivated uring reperfusion 
by toxic oxygen metabolites, and this inactivation is
directly responsible for limiting recovery of mechan- 
ical function, a' 5, 24 This loss of myocardial CK activ- 
ity during reperfusion is the result of oxidation of its 
thiol groups and does not result, as we have previ- 
ously shown, from washout of CK from damaged 
cells. 4 This inactivation is responsible at least in part 
for lower ATP levels as a result of the impaired 
transfer of high-energy phosphates between phos- 
phocreatine and adenosine diphosphate. As a result, 
less ATP is available to sustain myofibrillar activity. 4
CoQ~0 hearts showed higher CK activity as well as 
higher ATP levels during reperfusion, both of which 
are consistent with improved CK activity during 
reperfusion provided by CoQ10. Although the mech- 
anism is not specifically addressed in this study, CK 
protection is almost certainly the result of CoQ~o 
antioxidant activity because oxidation is the primary 
mechanism for reperfusion-induced inactivation. 
Another mechanism that may explain higher levels 
of myocardial CK activity during reperfusion in 
CoQ10 hearts is the ability of CoQ10 to stabilize cell 
membranes, sa On the basis of the results of previous 
experiments in which we showed no significant 
increment of CK in the coronary effluent during 
reperfusion, we believe that cell membrane l akage 
is not responsible for loss of CK activity during 
reperfusion, and stabilization of cell membranes by 
CoQ~0 is therefore not the mechanism responsible 
for the protection of CK activity during reperfusion. 
Finally, CoQt0 pretreatment preserves DP/MVo 2 
during reperfusion with respect to that in the control 
group. Hearts stunned by ischemia-reperfusion c - 
sume more oxygen to generate less pressure than 
during equilibration and are therefore less effi- 
cient. 34-3s Several authors have shown that mito- 
chondrial function is not the limiting factor in 
recovery of mechanical function in stunned myocar- 
dium. 37-40 Rather, alterations in electromechanical 
coupling, ionic transport (calcium channels, ATP- 
dependent potassium channels), and muscle con- 
traction are principally involved in the increased 
cost of contraction i  the stunned myocardium with 
respect to MY02 .41-46 COQlo may protect reperfused 
myocardium through its antioxidant and membrane- 
stabilizing properties, as well as through its ability to 
increase ATP levels to support energy-consuming 
processes, allowing DP/MVo2 to remain at normal 
levels. 
Conclusions 
We conclude from these experiments hat CoQ~o 
pretreatment effectively increases myocardial COQlo 
levels, leading to an improved tolerance to myocar- 
dial reperfusion injury. This improvement results 
from the effects of COQlo on mitochondrial function 
and antioxidant activity. CoQlo increases myocardial 
energy production, protects CK during reperfusion, 
preserves DP/MVo2, and improves mechanical func- 
tion after ischemic insult. 
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Discussion 
Dr. Pedro J. del Nido (Boston, Mass.). I congratulate 
you on an elegant study and thank you for sending me the 
manuscript ahead of time. 
This is an important mechanism that you have outlined 
here, and one that has been studied by several investiga- 
tors in the past. All have also demonstrated that CoQao is 
very effective, with both experimental studies and, I may 
now add, human data showing that it may in fact be useful. 
The important aspect of your study is that you have 
convincingly demonstrated that the mechanism may in 
fact be its antioxidant protection of CK. One of the major 
effects of the presence of CK is to lower free ATP levels; 
the free energy of ATP hydrolysis, which is required to 
drive the calcium pumps, is thus preserved. 
You have available, however, a means of measuring the 
activity of CK in vivo by performing saturation transfer 
experiments with NMR and measuring the free energy of 
ATP hydrolysis. Have you done those experiments to 
corroborate the in vitro assays of CK enzyme activity? 
Second, with respect o the question of whether the 
CoQjo is actually used, have you looked at UB1QUINOL 
levels in these hearts after administration? 
Dr. Crestanello. We have not looked at CK activity 
through saturation transfer or looked at the free energy of 
ATP hydrolysis in this animal model, but we have plans to do 
that. 
Regarding your second question on the UBIQUINOL 
levels in the heart, we measured them. Those are the 
levels that we have shown as the levels of CoQlo in the 
myocardium. 
Dr. Michael A. Rowland (Melbourne, Australia). I com- 
mend you for tackling the difficult question of the mech- 
anism of action of this important and interesting com- 
pound. The improved postischemic DP/MVo2, higher 
ATP and phosphocreatine levels, and preservation of CK 
activity are all indicative of a myoprotective effect. You 
would expect o see these with other forms of protection, 
such as hypothermia or cardioplegia, and they are not 
specific to CoQlo. 
The mechanism of this effect probably relates to CoQio 
as a potent free radical scavenger, which brings me to my 
first question. Did you measure indexes of oxidative stress 
such as thiobarbituric acid-reactive substances or reduced 
oxidized glutathione ratio? If so, was there a difference 
between the two groups? 
Second, I was interested to see the elevated levels of 
phosphocreatine and ATP in prestress measurements of 
the treated group. Does this represent a supernormal level 
of high-energy phosphates, or is this a reflection of the 
myoprotective effects of COQlo against he insult to the 
heart of the setting and preparation? 
Finally, we believe that another protective action of 
CoQlo may play an important role, particularly in the 
senescent myocardium. The unique position of CoQao as 
a mobile electron carrier within the mitochondrial mem- 
brane enables it to maintain the flow of energy and sustain 
ATP production in the face of both acute and chronic free 
radical injury to the mitochondrial membrane and the 
protein complexes. To what extent do you think that this 
mechanism could be operational in your model? 
Dr. Crestaneno. Regarding your first question, if we 
have looked at other ways to measure oxidative stress in 
our model, we have used lucigenin-enhanced chemilumi- 
nescence to continuously and directly measure free oxy- 
gen radical production. We have shown that hearts pre- 
treated with CoQlo had lower levels of oxidative stress 
than control hearts. 
Regarding your second question about he higher levels 
of high-energy phosphates at equilibration before the 
ischemic insult, we attribute this effect of CoQw to the 
improvement in oxidative phosphorylation a d respiratory 
chain efficiency. Regarding your last question, I agree that 
the last mechanism you outlined is very important, and it 
could also explain our results. 
